景峰医药(000908) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit loss between 15 million to 25 million yuan for the reporting period, compared to a loss of 12.84 million yuan in the same period last year[2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 18 million to 27 million yuan, compared to a loss of 19.42 million yuan last year[2]. - The expected basic earnings per share will be a loss between 0.0170 yuan to 0.0284 yuan, compared to a loss of 0.0146 yuan per share last year[2]. - Operating revenue is anticipated to be between 180 million to 220 million yuan, significantly down from 380.52 million yuan in the previous year[2]. Reasons for Decline - The decline in financial indicators is attributed to the exclusion of the important subsidiary Dalian Dezhe Pharmaceutical Co., Ltd. from the consolidated financial statements[3]. - The company faced lower-than-expected sales due to insufficient outsourced processing production of key products from its subsidiary Shanghai Jingfeng Pharmaceutical Co., Ltd.[6]. Financial Reporting - The financial data provided is preliminary and has not been audited by an accounting firm, with detailed figures to be disclosed in the 2024 semi-annual report[7].